Why the study?
This systematic review aimed to assess current knowledge on the clinical pharmacokinetics of vildagliptin to provide recommendations for clinical use and prevent harmful effects.
What are the clinical pharmacokinetics of vildagliptin in healthy and disease populations?
What are the clinical pharmacokinetics of vildagliptin in healthy and disease populations?
This systematic review summarizes the clinical pharmacokinetics of vildagliptin to aid in dose optimization, particularly for patients with renal impairment.
Supports vildagliptin dose optimization in renal impairment to minimize toxicity; extends synthesized PK data for special populations.
INTRODUCTION: Vildagliptin, a dipeptidyl peptidase-4 inhibitor, is indicated to cure type 2 diabetes mellitus (T2DM). This systematic literature search aims to assess the current knowledge about the clinical pharmacokinetics (PK) of vildagliptin to provide recommendations for clinical use to prevent the harmful effects of this drug. METHODS: The PubMed, Science Direct, EBSCO, Cochrane Central Register of Controlled Trials, and Google Scholar databases were screened for articles related to the clinical PK of vildagliptin using systematic search strategies. RESULTS: The literature search identified 2118 records, among which 28 were subsumed in this systematic review that fulfilled the inclusion standards. CONCLUSIONS: This systematic review can help dose optimization among critically ill patients (e.g. renal impairment) without exposing them to the drug's toxic effects.
No takes yet. Share an insight, caveat, or question.
Pasha et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: